Actual LIBTAYO patient.
LIBTAYO is the first medicine approved by the Food and Drug Administration (FDA) to treat CSCC that has spread or cannot be cured by surgery or radiation. LIBTAYO is a type of immunotherapy called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.